探討靈芝免疫調節蛋白抑制肺癌細胞之Wnt/β-catenin訊息傳遞路徑

Down-regulation of Wnt/β-catenin signaling pathway in lung cancer cells by GMI, an immunomodulatory protein from Ganoderma microsporum

許人婕

Wnt/β-catenin訊息路徑 ； 肺癌細胞 ； 靈芝免疫調節蛋白 ； 表皮生長因子接受體 ； Wnt/β-catenin signaling pathway ； lung cancer ； Ganoderma microsporum ； epidermal growth factor receptor

中山醫學大學醫學研究所學位論文

2016年

碩士

柯俊良

繁體中文

在Wnt訊息路徑中，β-catenin為訊息傳遞路徑中重要的調節蛋白，其穩定性與入核現象被視為路徑活化的關鍵。Wnt訊息路徑所調控下游基因之表現與細胞存活、細胞侵襲和細胞抗藥性有密切關係。本實驗將探討在肺癌細胞是否藉由小孢子靈芝免疫調節蛋白(Fungal immunomodulatory protein- Ganoderma microsporum，GMI) 抑制Wnt訊息路徑之β-catenin表現量。經西方墨點法發現，GMI可有效抑制β-catenin蛋白表現量，並由核質分離法可發現GMI會抑制H1355細胞核和與細胞質的β-catenin蛋白量。以TOPFLASH/FOPFLASH reporter assay，GMI具有抑制β-catenin/Tcf 轉錄活性。RT-PCR與Real-time PCR結果發現，GMI具降低β-catenin下游基因cyclin-D1與survivin表現。透過CCK-8方法與流式細胞儀偵測GMI抑制肺癌細胞之細胞存活現象並促使細胞死亡。以Wnt3a刺激細胞可增加β-catenin蛋白而減少cleaved caspase 7，反之，將β-catenin基因關閉則可增加cleaved caspase 7表現。分別以MG132或LLnL (proteasome inhibitor) 或SB216763 (p-GSK3β抑制劑)處理細胞可抑制 GMI將β-catenin降解。在非小細胞肺癌中，具EGFR突變細胞具有高表現的β-catenin蛋白量。在EGFR雙重突變L858R/T790M細胞H1975對於GMI敏感，GMI可有效減少β-catenin，而以ICG-001 (Wnt/β-catenin/TCF 基因轉錄抑制劑，且專一結合於element-binding protein (CBP)) 可增加細胞死亡。本研究結果顯示，GMI可抑制β-catenin的表現進而抑制Wnt/β-catenin路徑與癌細胞增生，在EGFR雙重L858R/T790M突變細胞H1975也具有明顯的抑制效果，因此未來將進一步分析GMI抑制β-catenin後的下游基因表現與癌症增生的關係。

β-catenin play a central role in Wnt signaling pathway. Aberrant activation of Wnt/β-catenin signaling downstream genes, such as survivin, c-myc, cyclin D involved in cell resistant, cell survival and cell invasion. In this study, we investigated the effects of GMI, a recombinant fungal immunomodulatory protein from Ganoderma microsporum on β-catenin/Tcf signaling, apoptosis induction and β-catenin/Tcf transcription activity in lung cancer. Lung cancer cells were treated with GMI for cell viability and cell apoptosis measured by CCK-8 assay and flow cytometry analysis. Nuclear and cytoplasmic β-catenin protein level were inhibited by GMI analyzed on Western blot. In addition, proteasome inhibitors MG132 and LLnL or p-GSK3β inhibitors SB216763 prevented the degradation of β-catenin mediated by GMI. Stimulation of Wnt3a induced β-catenin and reduced cleaved caspase 7. Knockdown of β-catenin gene expression elevated cleaved caspase 7. GMI decreased β-catenin/Tcf transcription activity by TOPFLASH/FOPFLASH reporter assay. Survivin and cyclin D1 have been down-regulated by GMI on RT-PCR and real time PCR. Furthermore, NSCLC patients with epidermal growth factor receptor gene mutant had high expression of β-catenin. Our findings indicate that GMI can decrease β-catenin expression and induces cell death in H1975 (EGFR L858R/T790M mutate) lung cancer cells. GMI might be therapeutic agent targeting to EGFR-double mutation H1975 lung cancer cells. In conclusion, our data demonstrated that GMI reduced β-catenin and inhibits the Wnt signaling pathway in non-small cell lung cancer (NSCLC).

1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16: 3797-804
   連結：
2. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA (2009) Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-72
   連結：
3. Atkinson JM, Rank KB, Zeng Y, Capen A, Yadav V, Manro JR, Engler TA, Chedid M (2015) Activating the Wnt/beta-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One 10: e0125028
   連結：
4. Bazley LA, Gullick WJ (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12 Suppl 1: S17-27
   連結：
5. Bleckmann A, Siam L, Klemm F, Rietkotter E, Wegner C, Kramer F, Beissbarth T, Binder C, Stadelmann C, Pukrop T (2013) Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta-catenin in cerebral metastasis of lung adenocarcinomas. Clin Exp Metastasis 30: 471-82
   連結：
6. Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. Nature 443: 796-802
   連結：
7. Bullions LC, Levine AJ (1998) The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 10: 81-7
   連結：
8. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY (2001) Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. The Journal of cell biology 152: 87-96
   連結：
9. Chen X, Song X, Yue W, Chen D, Yu J, Yao Z, Zhang L (2015) Fibulin-5 inhibits Wnt/beta-catenin signaling in lung cancer. Oncotarget 6: 15022-34
   連結：
10. Chien RC, Yen MT, Tseng YH, Mau JL (2015) Chemical characteristics and anti-proliferation activities of Ganoderma tsugae polysaccharides. Carbohydr Polym 128: 90-8
    連結：
11. Chiu LY, Hu ME, Yang TY, Hsin IL, Ko JL, Tsai KJ, Sheu GT (2015) Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells. PLoS One 10: e0125774
    連結：
12. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v116-9
    連結：
13. Daniel JM, Reynolds AB (1997) Tyrosine phosphorylation and cadherin/catenin function. Bioessays 19: 883-91
    連結：
14. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18: 73-9
    連結：
15. Fabregat I (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15: 513-20
    連結：
16. Fang X, Gu P, Zhou C, Liang A, Ren S, Liu F, Zeng Y, Wu Y, Zhao Y, Huang B, Zhang Z, Yi X (2014) beta-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells. Pulm Pharmacol Ther 28: 41-8
    連結：
17. Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, Yoshimori T (2008) An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure. Mol Biol Cell 19: 4651-9
    連結：
18. Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 121: 4712-21
    連結：
19. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G (2007) Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14: 1237-43
    連結：
20. Gomez-Orte E, Saenz-Narciso B, Moreno S, Cabello J (2013) Multiple functions of the noncanonical Wnt pathway. Trends Genet 29: 545-53
    連結：
21. Green DR, Llambi F (2015) Cell Death Signaling. Cold Spring Harb Perspect Biol 7
    連結：
22. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313
    連結：
23. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30: 1122-8
    連結：
24. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-501
    連結：
25. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, Wang X, Jin H (2011) EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6: e18691
    連結：
26. Hao H, Nancai Y, Lei F, Xiong W, Wen S, Guofu H, Yanxia W, Hanju H, Qian L, Hong X (2008) siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells. J Exp Clin Cancer Res 27: 27
    連結：
27. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-12
    連結：
28. Herraez E, Gonzalez-Sanchez E, Vaquero J, Romero MR, Serrano MA, Marin JJ, Briz O (2012) Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm 9: 2565-76
    連結：
29. Hong Y, Yang J, Wu W, Wang W, Kong X, Wang Y, Yun X, Zong H, Wei Y, Zhang S, Gu J (2008) Knockdown of BCL2L12 leads to cisplatin resistance in MDA-MB-231 breast cancer cells. Biochim Biophys Acta 1782: 649-57
    連結：
30. Hoschuetzky H, Aberle H, Kemler R (1994) Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127: 1375-80
    連結：
31. Hsu HC, Hsu CI, Lin RH, Kao CL, Lin JY (1997) Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J 323 ( Pt 2): 557-65
    連結：
32. Huang CL, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, Kadota K, Ueno M (2008) Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 44: 2680-8
    連結：
33. Hwang SJ, Lee HW, Kim HR, Lee H, Shin CH, Yun SI, Lee DH, Kim DH, Kim KK, Joo KM, Kim HH (2016) Ubiquitin-specific protease 4 controls metastatic potential through beta-catenin stabilization in brain metastatic lung adenocarcinoma. Sci Rep 6: 21596
    連結：
34. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, Watanabe H, Saijo Y, Nukiwa T (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-6
    連結：
35. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106-30
    連結：
36. Jiang H, Xia J, Kang J, Ding Y, Wu W (2009) Short hairpin RNA targeting beta-catenin suppresses cell proliferation and induces apoptosis in human gastric carcinoma cells. Scand J Gastroenterol 44: 1452-62
    連結：
37. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49: 209-16
    連結：
38. Jiang J, Slivova V, Sliva D (2006) Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 29: 695-703
    連結：
39. Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee CT, Chung JH (2013) Alteration of the E-Cadherin/beta-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma. Korean J Pathol 47: 44-51
    連結：
40. Klionsky DJ, Nemchenko A (2011) There is more to autophagy than induction: regulating the roller coaster. Autophagy 7: 801-2
    連結：
41. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-6
    連結：
42. Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY (1995) A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. Eur J Biochem 228: 244-9
    連結：
43. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005a) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-92
    連結：
44. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B (2005b) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-101
    連結：
45. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-51
    連結：
46. Lee SB, Gong YD, Park YI, Dong MS (2013) 2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells. Biochem Biophys Res Commun 431: 746-52
    連結：
47. Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42
    連結：
48. Li C, Song G, Zhang S, Wang E, Cui Z (2015) Wnt3a increases the metastatic potential of non-small cell lung cancer cells in vitro in part via its upregulation of Notch3. Oncol Rep 33: 1207-14
    連結：
49. Li X, Cai L, Liang M, Wang Y, Yang J, Zhao Y (2008) ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec (Hoboken) 291: 593-600
    連結：
50. Liao CH, Hsiao YM, Hsu CP, Lin MY, Wang JC, Huang YL, Ko JL (2006) Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from Ganoderma tsugae in A549 human lung adenocarcinoma cell line. Mol Carcinog 45: 220-9
    連結：
51. Liao CH, Hsiao YM, Lin CH, Yeh CS, Wang JC, Ni CH, Hsu CP, Ko JL (2008) Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food Chem Toxicol 46: 1851-9
    連結：
52. Lin CH, Hsiao YM, Ou CC, Lin YW, Chiu YL, Lue KH, Chang JG, Ko JL (2010) GMI, a Ganoderma immunomodulatory protein, down-regulates tumor necrosis factor alpha-induced expression of matrix metalloproteinase 9 via NF-kappaB pathway in human alveolar epithelial A549 cells. J Agric Food Chem 58: 12014-21
    連結：
53. Lin CH, Sheu GT, Lin YW, Yeh CS, Huang YH, Lai YC, Chang JG, Ko JL (2010) A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry 45: 1537–1542
    連結：
54. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97: 4262-6
    連結：
55. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-39
    連結：
56. Ma H, Nguyen C, Lee KS, Kahn M (2005) Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24: 3619-31
    連結：
57. Mazieres J, He B, You L, Xu Z, Jablons DM (2005) Wnt signaling in lung cancer. Cancer Lett 222: 1-10
    連結：
58. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13: 528-38
    連結：
59. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-20
    連結：
60. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-8
    連結：
61. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-57
    連結：
62. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-94
    連結：
63. Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H (2012) Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer 76: 228-34
    連結：
64. Nakashima T, Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Huang CL (2008) Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients. Oncol Rep 19: 203-9
    連結：
65. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K (2007) Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67: 2046-53
    連結：
66. Okamoto J, Hirata T, Chen Z, Zhou HM, Mikami I, Li H, Yagui-Beltran A, Johansson M, Coussens LM, Clement G, Shi Y, Zhang F, Koizumi K, Shimizu K, Jablons D, He B (2010) EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene 29: 5969-75
    連結：
67. Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Chen X, Wang Y, KimCurran V, Liu L, Hu Q, Zhang J, Tang L, Zhou C (2012) Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 64: 155-60
    連結：
68. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-44
    連結：
69. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-46
    連結：
70. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R et al. (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17: 1160-8
    連結：
71. Ruan W, Wei Y, Popovich DG (2015) Distinct Responses of Cytotoxic Ganoderma lucidum Triterpenoids in Human Carcinoma Cells. Phytother Res 29: 1744-52
    連結：
72. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P (1996) Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-6
    連結：
73. Ryan BM, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-62
    連結：
74. Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS, Swanson SJ, Aaronson SA (2013) Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg 257: 548-54
    連結：
75. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-81
    連結：
76. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29
    連結：
77. Sierra JR, Cepero V, Giordano S (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 9: 75
    連結：
78. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-7
    連結：
79. Sowa ME, Bennett EJ, Gygi SP, Harper JW (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138: 389-403
    連結：
80. Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106: djt356
    連結：
81. Suarez-Arroyo IJ, Rios-Fuller TJ, Feliz-Mosquea YR, Lacourt-Ventura M, Leal-Alviarez DJ, Maldonado-Martinez G, Cubano LA, Martinez-Montemayor MM (2016) Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression. J Cancer 7: 500-11
    連結：
82. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4: e838
    連結：
83. Sutani A, Nagai Y, Udagawa K, Uchida Y, Koyama N, Murayama Y, Tanaka T, Miyazawa H, Nagata M, Kanazawa M, Hagiwara K, Kobayashi K (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95: 1483-9
    連結：
84. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, Gazdar AF, Fujisawa T (2007) Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 13: 6087-92
    連結：
85. Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-62
    連結：
86. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-37
    連結：
87. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M, West Japan Thoracic Oncology G (2008) Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-14
    連結：
88. Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC, Lai MK, Lin JY (2009) MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett 273: 35-43
    連結：
89. Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-6
    連結：
90. Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3: 233-45
    連結：
91. Thakur A, Rana M, Lakhanpal TN, Ahmad A, Khan MI (2007) Purification and characterization of lectin from fruiting body of Ganoderma lucidum: lectin from Ganoderma lucidum. Biochim Biophys Acta 1770: 1404-12
    連結：
92. Toss A, Cristofanilli M (2015) Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res 17: 60
    連結：
93. Van Scoyk M, Randall J, Sergew A, Williams LM, Tennis M, Winn RA (2008) Wnt signaling pathway and lung disease. Transl Res 151: 175-80
    連結：
94. Wang HQ, Xu ML, Ma J, Zhang Y, Xie CH (2012) Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Commun 417: 62-6
    連結：
95. Wang LR, Huang MZ, Xu N, Shentu JZ, Liu J, Cai J (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6: 446-50
    連結：
96. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK (1997) The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70: 699-705
    連結：
97. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB, Quan LP, Bai JF, Xu NZ (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7: R220-8
    連結：
98. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY (2016) The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget
    連結：
99. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, Huang YS, Yan HH, Ren S, Liu Y, Yang JJ (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24: 993-9
    連結：
100. Xie C, Pan Y, Hao F, Gao Y, Liu Z, Zhang X, Xie L, Jiang G, Li Q, Wang E (2014) C-Myc participates in beta-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells. APMIS 122: 1251-8
     連結：
101. Xu H, Kong YY, Chen X, Guo MY, Bai XH, Lu YJ, Li W, Zhou XW (2016) Recombinant FIP-gat, a Fungal Immunomodulatory Protein from Ganoderma atrum, Induces Growth Inhibition and Cell Death in Breast Cancer Cells. J Agric Food Chem 64: 2690-8
     連結：
102. Xu Z, Chen X, Zhong Z, Chen L, Wang Y (2011) Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med 39: 15-27
     連結：
103. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480: 118-22
     連結：
104. Yang Z, Klionsky DJ (2009) An overview of the molecular mechanism of autophagy. Curr Top Microbiol Immunol 335: 1-32
     連結：
105. Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, Kosaka T, Mitsudomi T, Hida T (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2: 22-8
     連結：
106. Yuan D, Liu L, Gu D (2007) Transcriptional regulation of livin by beta-catenin/TCF signaling in human lung cancer cell lines. Mol Cell Biochem 306: 171-8
     連結：
107. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-5
     連結：
108. Yun SI, Kim HH, Yoon JH, Park WS, Hahn MJ, Kim HC, Chung CH, Kim KK (2015) Ubiquitin specific protease 4 positively regulates the WNT/beta-catenin signaling in colorectal cancer. Mol Oncol 9: 1834-51
     連結：
109. Zhang G, Sun J, Wang H, Ng TB (2010) First isolation and characterization of a novel lectin with potent antitumor activity from a Russula mushroom. Phytomedicine 17: 775-81
     連結：
110. Zhao Y, Yang ZQ, Wang Y, Miao Y, Liu Y, Dai SD, Han Y, Wang EH (2010) Dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer. Mol Carcinog 49: 760-70
     連結：
111. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-42
     連結：
112. Zhu M, Chang Q, Wong LK, Chong FS, Li RC (1999) Triterpene antioxidants from ganoderma lucidum. Phytother Res 13: 529-31
     連結：
113. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K, Tsunoo H (1989) Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 264: 472-8
114. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544
115. Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo-Margareto J, Gewirtz DA, Kroemer G, Levine B, Mizushima N, Rubinsztein DC, Thumm M, Tooze SA (2010) A comprehensive glossary of autophagy-related molecules and processes. Autophagy 6: 438-48
116. Kren L, Hermanova M, Goncharuk VN, Kaur P, Ross JS, Pavlovsky Z, Dvorak K (2003) Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases. Cesk Patol 39: 17-20
117. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-8
118. Murasugi A, Tanaka S, Komiyama N, Iwata N, Kino K, Tsunoo H, Sakuma S (1991) Molecular cloning of a cDNA and a gene encoding an immunomodulatory protein, Ling Zhi-8, from a fungus, Ganoderma lucidum. J Biol Chem 266: 2486-93
119. Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N (2015) Elevated beta-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Sci Rep 5: 13076
120. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS (2014) beta-catenin contributes to lung tumor development induced by EGFR mutations. Cancer Res 74: 5891-902
121. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-500
122. Pyndiah S, Sakamuro D (2013) [c-MYC, PARP1 and BIN1 as targets for therapy of cancer cell resistance]. Med Sci (Paris) 29: 133-5
123. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M et al. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-60